Journal of Hepatology最新文献

{"title":"Metabolic dysfunction-associated steatotic liver disease a multisystem disease: assessing the cost effectiveness of pharmacotherapies","authors":"Christopher D. Byrne, Gregory J. Dore","doi":"10.1016/j.jhep.2025.02.001","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.02.001","url":null,"abstract":"No Abstract","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"128 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143385130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to: “Evaluating Fracture Risk with TDF in Elderly Hepatitis B Patients: A Korean Perspective”","authors":"Jimmy Che-To Lai, Jie Cai, Terry Cheuk-Fung Yip","doi":"10.1016/j.jhep.2025.01.038","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.01.038","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Acknowledgements</h2>None.</section></section><section><section><h2>Authors' contributions</h2>All authors were responsible for writing the article. All authors read and approved the final version of the manuscript.</section></section><section><section><h2>Financial support</h2>None declared.</section></section><section><section><h2>Declaration of Competing Interest</h2>Jimmy Lai has served as a speaker for Gilead Sciences and Abbott, and an advisory committee member for Gilead Sciences and Boehringer Ingelheim. Cai J declares that she has no competing interests. Yip TC has served as an advisory committee member and a speaker for Gilead Sciences and received a research grant from Gilead Sciences.Please refer to the accompanying ICMJE disclosure forms for further details.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"10 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143371533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to: “Optimizing Antiviral Prophylaxis Strategies: Insights and Reflections on a Real-World Study” and “Optimal Timing To Initiate Antiviral Prophylaxis of MTCT: More Required to Be Done”","authors":"Mingwang Shen, Shihao He, Naijuan Yao, Li Xie, Lei Zhang, Tianyan Chen","doi":"10.1016/j.jhep.2025.02.002","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.02.002","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Authors' contributions</h2>MS, LZ, TC, and SH conceived and designed the study. MS and SH analyzed the data, carried out the analysis, and performed numerical simulations. MS and SH wrote the first draft of the manuscript. MS, LZ, and TC critically revised the manuscript. All the authors contributed to writing the paper and agreed with the manuscript results and conclusions.</section></section><section><section><h2>Data availability statement</h2>All data relevant to the study are included in the article or in the Appendix.</section></section><section><section><h2>Financial support</h2>This work was supported by National Key R&amp;D Program of China (2022YFC2505100, 2022YFC2304900), the Construction project of first-class subjects in Ningxia higher education (NXYLXK2017B09), the National Natural Science Foundation of China (12171387 (MS), 81950410639 (LZ)); Outstanding Young Scholars Support Program (3111500001(LZ)); Xi'an Jiaotong University Basic Research and Profession Grant (xtr022019003(LZ), xzy032020032 (LZ)) and Xi'an Jiaotong University Young Scholar Support Grant</section></section><section><section><h2>Declaration of Competing Interest</h2>All authors declare that they have no competing interests.</section></section><section><section><h2>Acknowledgements</h2>None.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"26 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143371513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment coverage of the 2024 updated WHO guidelines for patients with chronic hepatitis B","authors":"Jian Wang, Shaoqiu Zhang, Chuanwu Zhu, Chao Wu, Rui Huang","doi":"10.1016/j.jhep.2025.01.039","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.01.039","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Authors' contributions</h2>Dr. Huang had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.Concept and design: Huang, Wang, Wu.Acquisition, analysis, or interpretation of data: All authors.Drafting of the manuscript: Wang, Huang.Critical review of the manuscript for important intellectual content: Huang, Wu.Statistical analysis: Wang, Zhang.Administrative, technical, or material support: Wang, Zhang, Zhu.Supervision: Huang.</section></section><section><section><h2>Data availability statement (delete if not applicable)</h2>For privacy protection, the dataset used in this study is available from the corresponding author upon reasonable request.</section></section><section><section><h2>Financial support</h2>Drs. Huang and Wang received grants from the Clinical Trials of the Affiliated Drum Tower Hospital, Medical School of Nanjing University (No. 2022-LCYJ-MS-07 and 2021-LCYJ-PY-43). No other disclosures have been reported.</section></section><section><section><h2>Declaration of Competing Interest</h2>The authors declare no conflicts of interest.</section></section><section><section><h2>Acknowledgements</h2>None.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"54 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143371549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revealing bias in feature importance through PLS-DA: A critical examination of machine learning applications in chronic liver disease.","authors":"Yoshiyasu Takefuji","doi":"10.1016/j.jhep.2024.12.021","DOIUrl":"10.1016/j.jhep.2024.12.021","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":" ","pages":""},"PeriodicalIF":26.8,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142864536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Freiburg Index of Post-TIPS Survival (FIPS) identifies patients at risk for further decompensation and ACLF after TIPS","authors":"Lukas Sturm, Michael Schultheiss, Fabian Stöhr, Christian Labenz, Benjamin Maasoumy, Anja Tiede, Michael Praktiknjo, Leon Louis Seifert, Timo Alexander Auer, Uli Fehrenbach, Felix Piecha, Aenne Harberts, Johannes Kluwe, Tony Bruns, Maike Rebecca Pollmanns, Johannes Chang, Jakub Grobelski, Christian Jansen, Carsten Meyer, Marlene Reincke, Dominik Bettinger","doi":"10.1016/j.jhep.2025.01.030","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.01.030","url":null,"abstract":"<h3>Background &amp; Aims</h3>The Freiburg Index of Post-TIPS Survival (FIPS) defines a high-risk group of patients with significantly reduced survival following transjugular intrahepatic portosystemic shunt (TIPS) implantation. However, the clinical hallmarks responsible for these patients’ unfavorable outcome remain to be identified. Therefore, the present study aimed to characterize the clinical course after TIPS implantation according to the FIPS.<h3>Methods</h3>A total of 1359 patients with cirrhosis allocated to TIPS implantation for treatment of recurrent or refractory ascites or secondary prophylaxis of variceal bleeding from eight tertiary centers were retrospectively included. The patients’ clinical course following TIPS placement was analyzed, stratified according to the FIPS. Primary study outcome was further decompensation of cirrhosis within 90 days after TIPS, secondary outcomes were acute-on-chronic liver failure (ACLF) within 90 days and one-year transplant-free survival.<h3>Results</h3>Further decompensation after TIPS implantation was significantly more frequent in FIPS high-risk patients compared to low-risk patients (cumulative incidence function 0.58 vs. 0.38, p &lt; 0.001). Moreover, FIPS high-risk patients developed ACLF significantly more often (0.18 vs. 0.08; p = 0.008). Uni- and multivariable competing risk regression analyses confirmed that the FIPS high-risk group independently predicted further decompensation (sHR 1.974, 95 % CI 1.531 – 2.544, p &lt; 0.001) and ACLF after TIPS (sHR 2.586, 95 % CI 1.449 – 4.616, p = 0.001). Importantly, further decompensation and ACLF after TIPS were associated with significantly reduced transplant-free survival.<h3>Conclusions</h3>The present study reveals that the FIPS predicts development of further decompensation and ACLF after TIPS implantation. These events are responsible for impaired transplant-free survival in FIPS high-risk patients. These results pave the way for the development of tailored clinical management strategies.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"7 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143083822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hyodeoxycholic acid ameliorates cholestatic liver fibrosis by facilitating m6A-regulated expression of a novel anti-fibrotic target ETV4","authors":"Xiaoyong Xue, Runping Liu, Yajie Cai, Liping Gong, Guifang Fan, Jianzhi Wu, Xin Li, Xiaojiaoyang Li","doi":"10.1016/j.jhep.2025.01.020","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.01.020","url":null,"abstract":"<h3>Background &amp; Aims</h3>Cholestatic liver fibrosis is a common pathological feature of various biliary tract diseases. the underlying pathological mechanisms are not fully elucidated, posing significant obstacles to the discovery of new drug targets. The current study aims to evaluate protective effects of hyodeoxycholic acid (HDCA) against cholestatic liver fibrosis and to ascertain whether ETV4 is a novel anti-fibrotic target involving in the therapeutic effects of HDCA.<h3>Methods</h3>The therapeutic effect of HDCA was verified using bile duct ligation (BDL) and <em>Abcb4</em>^<em>-/-</em> mouse models. <em>Etv4</em>^-/- mice were subjected to BDL to investigate the role of ETV4 in liver fibrogenesis and the therapeutic effects of HDCA. The <em>N</em>⁶-methyladenosine (m⁶A) modification was investigated using MeRIP-qPCR and IF/FISH techniques.<h3>Results</h3>HDCA levels were decreased in both cholestatic patients and mice, while HDCA supplementation significantly ameliorated cholestatic liver fibrosis. By inducing ETV4 expression in cholangiocytes, HDCA induced MMP9 secretion, facilitating extracellular matrix (ECM) degradation. Findings in cholestatic fibrosis patients and <em>Etv4</em>^-/- mice further revealed a promising role of ETV4 in improving liver fibrosis and in therapeutic effects of HDCA. Mechanistically, HDCA promoted m⁶A modification of <em>ETV4</em> mRNA, promotes IGF2BP1 recognition and PABPC1 recruitment to inhibit the deadenylation of <em>ETV4</em> mRNA, leading to increased mRNA stability, storage in P-bodies, and prolonged translation. The mutation of m⁶A site on <em>ETV4</em> mRNA or knocking down critical genes involved in m⁶A modification significantly abolished the regulative effects of HDCA.<h3>Conclusions</h3>The present study underscores ETV4 as a novel anti-fibrotic target and demonstrates that HDCA remodels ECM by facilitating m⁶A-regulated ETV4 expression, offering potential therapeutic approaches for cholestatic liver fibrosis.<h3>Impact and implications</h3>This study delves into the underlying mechanisms of cholestatic liver fibrosis and offers potential therapeutic targets. The research highlights ETV4 as a novel anti-fibrotic target and is essential for the therapeutic effects of hyodeoxycholic acid (HDCA) against cholestatic liver fibrosis. These findings are important for both the scientific community and patients with cholestatic liver diseases, offering valuable insights for future therapeutic strategies that focus on regulating m⁶A-dependent epigenetic modifications of anti-fibrotic targets like ETV4 and developing new interventions utilizing HDCA.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"55 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143124448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to: “The HDL criterion for MetALD can misclassify patients with cirrhosis”","authors":"David Marti-Aguado, José Luis Calleja, Ramon Bataller, Javier Crespo, María Teresa Arias-Loste","doi":"10.1016/j.jhep.2025.01.022","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.01.022","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Data availability statement (delete if not applicable)</h2>Data that support the findings of this study are available from the corresponding author upon reasonable request.</section></section><section><section><h2>Acknowledgements</h2>D.M.A. is recipient of a Joan Rodés award (JR22/00002), Instituto de Salud Carlos III (Spanish Ministry of Science and Innovation), and a grant Grupo de Investigación Emergente (CIGE/2022/37) from Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital, Generalitat Valenciana, Spain.Arial, normal, 12</section></section><section><section><h2>Authors' contributions</h2>D.M.A., JL.C., R.B., J.C., MT.A.L.: conception and design. D.M.A: statistical analysis and drafting of the manuscript. JL.C., R.B., J.C., MT.A.L.: critical revision and editing. All authors have reviewed and approved the final manuscript.</section></section><section><section><h2>Financial support</h2>The authors did not receive any financial support for this letter.</section></section><section><section><h2>Declaration of Competing Interest</h2>Authors declare no competing interest to declare regarding this manuscript.Please refer to the accompanying ICMJE disclosure forms for further details.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"133 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143083770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies","authors":"Homie A. Razavi, Imam Waked, Huma Qureshi, Loreta A. Kondili, Ann-Sofi Duberg, Soo Aleman, Junko Tanaka, Jeffrey V. Lazarus, Daniel Low-Beer, Zaigham Abbas, Antoine Abou Rached, Alessio Aghemo, Inka Aho, Ulus S. Akarca, Said A. Al-Busafi, Waleed K. Al-Hamoudi, Khalid Al-Naamani, Ahmed Sabry Alaama, Manahil M. Aldar, Mohammed Alghamdi, Eli Zuckerman","doi":"10.1016/j.jhep.2025.01.013","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.01.013","url":null,"abstract":"<h3>Background and aims</h3>The year 2023 marked the 10-year anniversary of the launch of direct-acting antivirals (DAAs) for the treatment of the hepatitis C virus (HCV). HCV treatment trends by country, region, and globally are important to monitor progress toward the World Health Organization’s 2030 elimination targets. Additionally, the historical patterns can help predict the treatment uptake for future therapies for other liver diseases.<h3>Methods</h3>The number of people living with HCV (PLHCV) treated between 2014–2023 across 119 countries was estimated using national HCV registries, reported DAA sales data, pharmaceutical companies’ reports, and estimates provided by national experts. For the countries with no available data, the average estimate of the corresponding Global Burden of Disease region was used.<h3>Results</h3>An estimated 13,816,000 (95% uncertainty intervals (UI): 13,221,000–16,415,000) PLHCV were treated, of whom 12,748,000 (12,226,000–15,231,000) were treated with DAAs, of which 11,081,000 (10,542,000–13,338,000) were sofosbuvir-based DAA regimens. Country-level data accounted for 97% of these estimates. In high-income countries, there was a 41% drop in treatment from its peak, and reimbursement was a large predictor of treatment. In low- and middle-income countries, price played an important role in expanding treatment access through the public and private markets, and treatment continues to increase slowly after a sharp drop at the end of the Egyptian national program.<h3>Conclusions</h3>In the last 10 years, 21% of all HCV infections were treated with DAAs. Regional and temporal variations highlight the importance of active screening strategies. Without program enhancements, the number of treated PLHCV stalled in every country/region which may not reflect a lower prevalence but may instead reflect the diminishing returns of the existing strategies.<h3>Impact and implications</h3>Long-term hepatitis C virus (HCV) infection can lead to cirrhosis and liver cancer. Since 2014, these infections can be effectively treated with 8-12 weeks of oral therapies. In 2015, the World Health Organization (WHO) established targets to eliminate HCV by 2030, which included treatment targets for member countries. The current study examines HCV treatment patterns across 119 countries and regions from 2014 to 2023 to assess the impact of national programs. This study can assist physicians and policymakers in understanding treatment patterns within similar regions or income groups and in utilizing historical data to refine their strategies in the future.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"7 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143083823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to: Unlock AI-Safe-C score's potential at all levels: Improve methods and overcome barriers","authors":"Huapeng Lin, Terry Cheuk-Fung Yip, Vincent Wai-Sun Wong, Victor de Lédinghen, Seung Up Kim","doi":"10.1016/j.jhep.2025.01.035","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.01.035","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Data availability statement (delete if not applicable)</h2>Data and results are available upon reasonable request to the corresponding author.</section></section><section><section><h2>Acknowledgements</h2>No acknowledgements for present study</section></section><section><section><h2>Authors' contributions</h2>Research design (H.L., SU.K.), data acquisition (all authors), data analysis (H.L., TC.Y.), manuscript draft (H.L., TC.Y., VW.W., SU.K.). All authors approved the final version of this manuscript.</section></section><section><section><h2>Financial support</h2>No funding for present study</section></section><section><section><h2>Declaration of Competing Interest</h2>Terry Yip has served as an advisory committee member and speaker at Gilead Sciences.Victor de Lédinghen has been an employee of Echosens since April 2024. This study was conducted while he was a Professor of Hepatology at Bordeaux University Hospital(France).Vincent Wong has served as a consultant or advisory board member for AbbVie, Boehringer Ingelheim, Echosens, Intercept, Inventiva, Novo Nordisk, Pfizer, andTARGET PharmaSolutions and a speaker for Abbott, AbbVie, Gilead Sciences, andNovo</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"96 5 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143077163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}